https://viralytics.com/wp-content/u...om-the-Oncolytics-Virus-Pack-at-AACR-2017.pdf
"In our view, the MITCI trial update stole the show given the unmet need in melanoma patients who fail front-line checkpoint therapies. We reiterate our Buy rating and AUD$2 PT"
Will this move the market?
Add to My Watchlist
What is My Watchlist?